Technology | September 24, 2007

Cordis Delivers New Balloons to U.S. Market


The FIRE STAR Rx PTCA Dilatation Catheter and the DURA STAR Rx PTCA Dilatation Catheter are indicated for expansion in the narrowed area of a coronary artery or bypass graft. The FIRE STAR Balloon features the lowest pre-dilatation profile in the market. It is equipped to enable interventional cardiologists to guide the catheter through tortuous arteries and to cross complex blockages, usually prior to the placement of a stent.

The DURA STAR Balloon facilitates the post-delivery expansion of stents in coronary arteries and is also suitable for tackling tortuous arteries and complex blockages. It has been designed to provide interventional cardiologists with controlled and even expansion of the balloon to the correct diameter, which may help reduce the potential for artery damage to the patient.

With its reportedly low pre-dilatation profile, the FIRE STAR Balloon is also designed for use in highly stenosed lesions and bifurcations. In addition, the FIRE STAR Balloon offers a controlled expansion for dilatation of arteries, which may help reduce the potential for artery damage. It also has a soft and tapered tip to facilitate crossing stent struts and challenging lesions, while its shaft construction helps to reduce the risk of kinking. The device is finished with a lubricating coating and is available in various lengths and diameters ranging from 10 mm to 30 mm and from 1.5 mm to 3.5 mm, respectively.

The DURA STAR Balloon is suited for use with both drug-eluting and bare-metal balloon-expandable stents. Its short and soft tip facilitates crossing stent struts and complex lesions. Equipped with a lubricating coating is intended to ease delivery to the site of a lesion. The balloon is available in various lengths from 10 to 30 mm and from 2.25 to 4.0 mm in diameter.

The U.S. Food and Drug Administration approved the commercialization of these products in late August.

For more information: www.cordis.com


Related Content

News | Balloon Catheter

April 4, 2024 — The U.S. Food and Drug Administration (FDA) announced that Medos International Sàrl is recalling ...

Home April 04, 2024
Home
News | Balloon Catheter

January 18, 2024 — Summa Therapeutics, LLC announced that the first-in-man injectable angioplasty procedures for ...

Home January 18, 2024
Home
News | Balloon Catheter
Cardiovascular Systems, Inc., a medical device company developing and commercializing innovative interventional ...
Home February 25, 2022
Home
News | Balloon Catheter

February 15, 2022 – CERENOVUS, an emerging leader in neurovascular care and part of Johnson & Johnson Medical Devices ...

Home February 15, 2022
Home
News | Balloon Catheter

May 20, 2021 — Boston Scientific Corporation announced it has initiated the AGENT IDE trial for the Agent Drug-Coated ...

Home May 20, 2021
Home
Feature | Balloon Catheter | By Dave Fornell, Editor

The first devices developed for interventional cardiology were percutaneous transluminal coronary angioplasty (PTCA) ...

Home March 16, 2021
Home
Feature | Balloon Catheter

February 17, 2021 — The U.S. Food and Drug Administration (FDA) has cleared Shockwave Medical's Intravascular ...

Home February 17, 2021
Home
News | Balloon Catheter

June 4, 2020 — Transit Scientific announced the U.S. Food and Drug Administration (FDA) cleared the XO Score ...

Home June 04, 2020
Home
News | Balloon Catheter

February 24, 2020 — Abbott has voluntarily recalled specific lots of two types of its coronary angioplasty catheters — ...

Home February 24, 2020
Home
News | Balloon Catheter

July 15, 2019 — Edwards LifeSciences is recalling the IntraClude Intra-Aortic Occlusion Device due to a risk of balloon ...

Home July 15, 2019
Home
Subscribe Now